Urodynamic testing

Pelvital Announces Advisory Board, Fueling its Mission to Transform the Standard of Care for Urinary Incontinence

Retrieved on: 
Tuesday, April 2, 2024
University, Obstructive sleep apnea, Patient, Pelvic pain, Vocational education, Urodynamic testing, Engineering, Gender, Champaign–Urbana metropolitan area, Pelvic organ prolapse, Carlson School of Management, UnitedHealth Group, Incontinence, Woman, Safety, Strategic communication, Organization, Biomedical engineering, Advisory board, Neurology, Female, Sport, Associate, Research, MD, UIT, Tetraplegia, Urinary incontinence, Biology, Book, FDA, Medtech, Health, Visibility, Growth, Computational biology, Arizent, Mechanical engineering, Physiology, M Health Fairview, Doctor of Philosophy, Integrative Biology, Faculty, Urogynecology, Human, MBA, News, Government, Rehabilitation, Nursing

EAGAN, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- Pelvital, the women's health MedTech company on a mission to transform the standard of care for urinary incontinence, is proud to announce the formation of its formal scientific and business advisory board. This dynamic team of industry leaders and experts will play a pivotal role in supporting the strategic direction and growth of the organization in its ongoing efforts to expand its reach with clinicians, patients, and payors seeking an effective, accessible, conservative treatment option.

Key Points: 
  • EAGAN, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- Pelvital, the women's health MedTech company on a mission to transform the standard of care for urinary incontinence, is proud to announce the formation of its formal scientific and business advisory board.
  • The seven-person advisory board assembles a wealth of experience and expertise with each member having a proven track record of excellence.
  • Dr. Alpert has taught for many years in entrepreneur programs at U.S. and overseas universities, mentoring students and faculty working in the healthcare industry.
  • Their collective knowledge and experience will be instrumental in guiding Pelvital as we embark on an exciting phase of growth and innovation."

Laborie Medical Technologies Invests in Medical Technology Start-Up Bright Uro

Retrieved on: 
Thursday, November 30, 2023
Incontinence, Urine, Woman, Pressure, Lower urinary tract symptoms, Investor AB, Patient, System, Urethra, LUTS, Urinary incontinence, Standard of care, Test management, Urodynamic testing, Management, Urology, Gleaning

PORTSMOUTH, N.H., Nov. 30, 2023 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.

Key Points: 
  • PORTSMOUTH, N.H., Nov. 30, 2023 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.
  • Founded in 2021, Bright Uro is developing the Glean Urodynamic System™, a wireless, catheter-free, urodynamic monitoring system intended to quantify the pressure characteristics of the lower urinary tract.
  • "We're thrilled to be working with Laborie," says Bright Uro Founder & CEO Derek Herrera.
  • "Laborie looks forward to leveraging our expertise and leadership in the global urodynamics market to support the Bright Uro team," said Michael Frazzette, President & CEO of Laborie Medical Technologies.

Versameb Appoints Professor Roger Dmochowski as Chief Medical Officer

Retrieved on: 
Wednesday, June 21, 2023
Abstract, Therapy, SUI, Incontinence, American Urological Association, Coronavirus Scientific Advisory Board, Woman, International Continence Society, RNA, Regenerative medicine, Urinary incontinence, American Board of Commissioners for Foreign Missions, US, Regeneration, Growth, Trustee, American College, Health, FDA, IND, Urology, Pharmaceutical industry, Urodynamic testing

BASEL, Switzerland, June 21, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer with immediate effect.

Key Points: 
  • BASEL, Switzerland, June 21, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer with immediate effect.
  • Professor Dmochowski is a renowned urologist and researcher, widely recognized for his contributions to the field of urologic health and clinical development.
  • Professor Dmochowski is the immediate past Editor-in-Chief of Neurourology and Urodynamics and serves on the editorial board for several scientific journals.
  • Professor Roger Dmochowski, newly appointed Chief Medical Officer of Versameb, commented: "I am eager to contribute my expertise to advance VMB-100 which has demonstrated functional recovery and tissue regeneration in preclinical models for the unmet medical need of SUI.

Versameb Appoints Professor Roger Dmochowski as Chief Medical Officer

Retrieved on: 
Wednesday, June 21, 2023
Abstract, Therapy, SUI, Incontinence, American Urological Association, Coronavirus Scientific Advisory Board, Woman, International Continence Society, RNA, Regenerative medicine, Urinary incontinence, American Board of Commissioners for Foreign Missions, US, Regeneration, Growth, Trustee, American College, Health, FDA, IND, Urology, Pharmaceutical industry, Urodynamic testing

BASEL, Switzerland, June 21, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer with immediate effect.

Key Points: 
  • BASEL, Switzerland, June 21, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer with immediate effect.
  • Professor Dmochowski is a renowned urologist and researcher, widely recognized for his contributions to the field of urologic health and clinical development.
  • Professor Dmochowski is the immediate past Editor-in-Chief of Neurourology and Urodynamics and serves on the editorial board for several scientific journals.
  • Professor Roger Dmochowski, newly appointed Chief Medical Officer of Versameb, commented: "I am eager to contribute my expertise to advance VMB-100 which has demonstrated functional recovery and tissue regeneration in preclinical models for the unmet medical need of SUI.

Gemini partners with UroGPO, a Specialty Networks Company

Retrieved on: 
Wednesday, January 18, 2023
Atmos, Partnership, Senior, Eurosport 1, Patient, Non-functional testing, Urodynamic testing, Physician, Health insurance

Boca Raton, FL, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gemini Medical Technologies, a privately held U.S.-based urodynamics diagnostics manufacturer, announced a new partnership today with UroGPO, a Specialty Networks Company, that will give urologists a new option for diagnostic testing.

Key Points: 
  • Boca Raton, FL, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gemini Medical Technologies, a privately held U.S.-based urodynamics diagnostics manufacturer, announced a new partnership today with UroGPO, a Specialty Networks Company, that will give urologists a new option for diagnostic testing.
  • “UroGPO and Specialty Networks have recognized an increased need for our members to gain access to new options, specifically in the Urodynamic catheter market.
  • As such, we have responded with developing what we believe is an extremely beneficial partnership with Gemini on their Atmos product line.
  • We are pleased to add Gemini and their Atmos product line to the list of UroGPO industry partners and products.” said Darren J Dieleman, Senior Vice President of Specialty Networks, LLC.

Global Urodynamics Equipment and Disposables Market Report 2022: Introduction of Technologically Advanced Products Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022
Medical Devices, Health, Ansoff Matrix, Risk, Observation, Growth, SWOT, CAGR, Porter's five forces analysis, Investment, Geography, Industry, Ambulatory Surgery Center Association, Urodynamic testing, COVID-19, USD, Market development, Retail, Risk management, Medical device, Hospital

The Global Urodynamics Equipment and Disposables Market is segmented based on Product, End-users, and Geography.

Key Points: 
  • The Global Urodynamics Equipment and Disposables Market is segmented based on Product, End-users, and Geography.
  • By Product, the market is classified into Uroflowmetry Equipment, Cystometer, Ambulatory Urodynamic Systems, Electromyographs, Video Urodynamic Systems, and Urodynamics Disposables.
  • The report presents a detailed Ansoff matrix analysis for the Global Urodynamics Equipment and Disposables Market.
  • The report offers a comprehensive evaluation of the Global Urodynamics Equipment and Disposables Market.

Published studies find low documented adherence to guideline-based care for female urinary incontinence

Retrieved on: 
Friday, July 22, 2022
Diagnosis, Obstetrics & Gynecology (journal), Instagram, Use, UI, Adult, SUFU, Cough, LinkedIn, American Urological Association, American College of Obstetricians and Gynecologists, AUA, American College, Obstetrics, Smartphone, Research, Woman, PFMT, Solution, Pelvic floor, Medical Affairs Bureau, Society, Urinary incontinence, Doctor of Pharmacy, All rights reserved, Storey, Engineering, Physician, Overactive bladder, Twitter, Female, ACOG, Sexual dysfunction, Health, Femtech, Quality of life, PDT, FDA, DPT, MUI, FI, Exertion, SUI, Sneeze, Feces, Time, MPH, Urine, Hotel manager, Rehabilitation, Physical, Movement, Mental health, Senior, Patient, PT, Medical device, Medical imaging, Health insurance, Birth control, Gynaecology, Kegel exercise, Gynaecology, Facebook, Urodynamic testing

BOSTON, July 22, 2022 /PRNewswire/ -- Renovia Inc. (Renovia), a developer of non-surgical treatments for female pelvic floor disorders and an advocate for women's health, announced today that Neurourology and Urodynamics published two studies demonstrating low rates of documented adherence to treatment guidelines for female urinary incontinence (UI) care for women and the effect on payer costs. One study showed significantly higher costs for payers in the two years following diagnosis for women whose treatment claims did not align with published guidelines for female UI. A second study showed very low use of physical therapy (PT) for UI, a discipline commonly engaged in first-line care for UI.

Key Points: 
  • BOSTON, July 22, 2022 /PRNewswire/ -- Renovia Inc. (Renovia), a developer of non-surgical treatments for female pelvic floor disorders and an advocate for women's health, announced today that Neurourology and Urodynamics published two studies demonstrating low rates of documented adherence to treatment guidelines for female urinary incontinence (UI) care for women and the effect on payer costs.
  • A second study showed very low use of physical therapy (PT) for UI, a discipline commonly engaged in first-line care for UI.
  • Numerous studies show PFMT isan effective treatment for urinary incontinence and that PFMT, commonly referred to as Kegels, is challenging for women to implement effectively on their own.
  • The study determined that documented care not sequenced in adherence to guidelines increasedpayers' cost burden.

Published health economics study shows improved treatment for female urinary incontinence may have positive effect on patient outcomes and healthcare costs

Retrieved on: 
Tuesday, June 21, 2022
PT, Rehabilitation, Cough, Pelvic floor, Smartphone, LinkedIn, Obstetrics, Urine, University, Keck School of Medicine of USC, Health, MUI, Associate, Urinary incontinence, Division, Obstetrics & Gynecology (journal), Incontinence, Therapy, Female, UI, Use, Storey, PDT, Sneeze, Twitter, Movement, PFMT, FDA, Urogynecology, All rights reserved, Medical Affairs Bureau, Sexual dysfunction, Exertion, SUI, Adult, Patient, Multimedia, Instagram, Woman, Safety, Research, Kegel exercise, Overactive bladder, Femtech, Pharmaceutical industry, Health insurance, Birth control, Medical imaging, Gynaecology, Urodynamic testing, Medicine, Facebook

BOSTON, June 21, 2022 /PRNewswire/ -- Renovia Inc. (Renovia), a women-led company that develops digital therapeutics for female pelvic floor disorders, announced today that a recent peer-reviewed, published study showed that women with stress urinary incontinence (SUI) and mixed urinary incontinence (MUI) consume significantly more medical resources and incur higher costs to payers, compared to women without SUI/MUI.  The study was published in Neurourology and Urodynamics, the official journal of the Society of Urodynamics and Female Pelvic Medicine & Urogenital Reconstruction.

Key Points: 
  • The study was published in Neurourology and Urodynamics , the official journal of the Society of Urodynamics and Female Pelvic Medicine & Urogenital Reconstruction.
  • The study, "Healthcare Resource Use and Cost Burden of Urinary Incontinence to United States Payers," assessed healthcare resource utilization and costs for female patients diagnosed with stress or mixed urinary incontinence (SUI/MUI) compared to a 1:1 matched cohort of patients without SUI/MUI.
  • Urinary incontinence (UI) is a highly prevalent health condition experienced by over 60% of adult women.
  • Multiple studies show that Pelvic Floor Muscle Training (PFMT), commonly referred to as Kegel exercises, can offer effective, first-line treatment for urinary incontinence.

Bright Uro Launches with $6 Million in Seed Financing and Grant from National Institutes of Health

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, General Health, Health, Medical Devices, Phase II, Urodynamic testing, Uro, OAB, Urine, Overactive bladder, Standard of care, CEO, NIH, Urology, United States Department of Veterans Affairs, Non-functional testing, Physician, Health, BPH, National, Patient, Technology, Cleveland Clinic, Diagnosis, Special operations, Case Western Reserve University, Department, Efficiency, LUTS, Parker Hannifin, Pharmaceutical industry, Medical imaging, Gleaning

Bright Uro was also awarded a $2 million Phase II SBIR grant from the National Institutes of Health (NIH).

Key Points: 
  • Bright Uro was also awarded a $2 million Phase II SBIR grant from the National Institutes of Health (NIH).
  • Bright Uro fulfills the promise of digital health, with more accurate and flexible diagnosis, at a decreased cost.
  • Bright Uros Glean Urodynamics System is designed to improve the patient and clinician experience with increased accuracy and comfort.
  • Bright Uro has obtained exclusivity to the catheter-free method used with the Glean system through a licensing agreement with Cleveland Clinic.

American Urological Association Announces Updates to Clinical Guidance for Interstitial Cystitis

Retrieved on: 
Tuesday, May 10, 2022
Health policy, AUA, Society, Pelvic pain, Urinary bladder, University, Pain, Guideline, Diagnosis, Lower urinary tract symptoms, Urodynamic testing, Urology, Patient, Infection, American Urological Association, Time-invariant system, Literature, Pressure, Female, Cystoscopy, Education, SUFU, Research, Sensation, IC/BPS, Medical device, Medical imaging, MD

"An important component of that clinical framework is discussion of treatments that should and should not be offered.

Key Points: 
  • "An important component of that clinical framework is discussion of treatments that should and should not be offered.
  • This approach reinforces that the clinical approach for IC/BPS needs to be individualized ad based on the unique characteristics of each patient.
  • A summary of the guideline also appears at:
    Clemens JQ, Erickson DR, Varela NP et al: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome.
  • About the American Urological Association: Founded in 1902 and headquartered nearBaltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology and has nearly 24,000 members throughout the world.